ReviewPharmacoEconomics2019
Transparency in Decision Modelling: What, Why, Who and How?
Review in PharmacoEconomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.PharmacoEconomics · 2020Pooled it
- A Technology Selection Tool Applying Multiple Criteria Decision Analysis for Virtual Care Implementation.Mayo Clinic proceedings. Digital health · 2025Article
- Charting the path to the implementation of universal health coverage policy in Nigeria through the lens of Delphi methodology.BMC health services research · 2025Article
- The PHEM-B toolbox of methods for incorporating the influences on Behaviour into Public Health Economic Models.BMC public health · 2024Article
- Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results.PharmacoEconomics · 2024Article
- A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening.Applied health economics and health policy · 2024Article
- A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel Consultations.PharmacoEconomics · 2024Article
- Paving the path for implementation of clinical genomic sequencing globally: Are we ready?Health affairs scholar · 2024Article
- Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network.PharmacoEconomics · 2022Article
- Four Aspects Affecting Health Economic Decision Models and Their Validation.PharmacoEconomics · 2022Article
- Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time.PharmacoEconomics · 2022Article
- Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020Article
- Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020Article
- A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling.PharmacoEconomics · 2019Article
- Improving Transparency in Decision Models: Current Issues and Potential Solutions.PharmacoEconomics · 2019Article
- Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States.PharmacoEconomics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Transparency in decision modelling is an evolving concept. Recently, discussion has moved from reporting standards to open-source implementation of decision analytic models. However, in the debate about the supposed advantages and disadvantages of greater transparency, there is a lack of definition. The purpose of this article is not to present a case for or against transparency, but rather to provide a more nuanced understanding of what transparency means in the context of decision modelling and how it could be addressed. To this end, we review and summarise the discourse to date, drawing on our collective experience. We outline a taxonomy of the different manifestations of transparency, including reporting standards, reference models, collaboration, model registration, peer review and open-source modelling. Further, we map out the role and incentives for the various stakeholders, including industry, research organisations, publishers and decision makers. We outline the anticipated advantages and disadvantages of greater transparency with respect to each manifestation, as well as the perceived barriers and facilitators to greater transparency. These are considered with respect to the different stakeholders and with reference to issues including intellectual property, legality, standards, quality assurance, code integrity, health technology assessment processes, incentives, funding, software, access and deployment options, data protection and stakeholder engagement. For each manifestation of transparency, we discuss the 'what', 'why', 'who' and 'how'. Specifically, their meaning, why the community might (or might not) wish to embrace them, whose engagement as stakeholders is required and how relevant objectives might be realised. We identify current initiatives aimed to improve transparency to exemplify efforts in current practice and for the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.